http://www.completegenomics.com/public-data/cancer-data/
http://www.completegenomics.com/services/cancer/
Quote:
"The Nature paper by Peters et al. describes how our LFR technology uses ‘barcoded' DNA to generate whole genome sequencing with approximately one error in 10 million base pairs, or just 600 errors in an entire human genome," said Dr. Rade Drmanac, the company's chief scientific officer and inventor of the LFR technology. "This represents a 10-fold increase in accuracy for Complete and is unmatched by any high-sensitivity method currently available."
In addition, Complete's LFR technology provides, for the first time, accurate whole-genome sequencing from as few as 10 to 20 cells (only 100 picograms of DNA), making it an ideal choice for small sample clinical sequencing applications including circulating tumor cells, fine needle aspirations, and pre-implantation genetic diagnostics
More quotes:Gene sequencing companies, which also include bigger names Illumina Inc and Life Technologies Corp, cater to a client base that mostly comprise educational and research institutions and compete on price.
The sector has recently come under pressure from a cut in the funding provided by the National Institutes of Health (NIH) for basic science research.
As the technology is yet to see widespread commercial adoption, the funding cut is one of the biggest issues faced by the sector that is on a persistent drive to bring down the price of gene sequencing to about $1,000.
Currently, the average price is $4,000-$5,000.
My take: This price is affordable for some patients. Comparible to the $2000 charged by Oncotype DX, and BRCA testing and others, generate a lot more information. Its accuracy and how little sample it takes (CTC) is a big sell for me.
Some types of BC has tumor mutations that are not standard BC, more like standard other cancer, which may have well targetted drugs for them. It could perhaps help your onco find a better targetted 2nd/3rd/4th line chemo/biological and gave the patient valuable time with better tolerance. It could give researchers more insight on why you are or are not responding to certain treatment or become resistant. It could in future change the way clinical trials are run and lead to the cure. Faster, more accurate, cheaper.
So my Cato bit: support research, support clinical trials to find the MBC cure. Note the NIH funding cut, the public needs to invest more money into basic science, better technologies and finding the cure, and spend less money on expensive tests/procedures/drugs/charities that really don't deliver the bang for the buck.
Except they are having trouble convincing doctors to use them. Here is where patients could come in. Patients have the right and the duty to demand the newest and best and cheapest technologies, to encourage innovation and save money for themselves and for the health care system. Illumina's 90% market share is not healthy for the development of this nascent market and notice how Illumina had to drop their price from $20000 to $4000 due to the new entrants into this market.
Quote from wikipedia:
Quote from wikipedia:
In June 2009, Illumina announced the launch of their own Personal Full Genome Sequencing Service at a depth of 30X for $48,000 per genome,[1] and a year later dropped the price to $19,500.[2] This is still too expensive for true commercialization but the price will most likely decrease substantially over the next few years as they realize economies of scale and given the competition with other companies such as Complete Genomics and Knome.[3][4] As of May 2011, Illumina reduced the price to $4,000.[5][6]
No comments:
Post a Comment